OncoMatch/Clinical Trials/NCT05929495
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
Is NCT05929495 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Metformin for glioblastoma, idh-wildtype.
Treatment: Metformin — About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. The clinical trial will be single-arm to evaluate the biological activity and effects of metformin in combination with TMZ in patients with GBM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
IDH wild type
Allowed: MGMT hypomethylation
hypomethylation or hypermethylation of MGMT assessed post-surgery
Allowed: MGMT hypermethylation
hypomethylation or hypermethylation of MGMT assessed post-surgery
Disease stage
Required: Stage IV (WHO)
Grade: IV (WHO)
WHO grade IV, IDH wild type
Prior therapy
Must have received: surgical resection
undergoing surgical resection
Must have received: Stupp protocol
Patients undergoing Stupp protocol including patients aged > 70 years performing the hypofractionated protocol and three weeks of chemotherapy
Cannot have received: metformin (metformin)
taking metformin, insulin or other biguanides, regardless of the reason
Cannot have received: insulin (insulin)
taking metformin, insulin or other biguanides, regardless of the reason
Cannot have received: biguanide
taking metformin, insulin or other biguanides, regardless of the reason
Lab requirements
Kidney function
impaired renal function with creatinine clearance < 60 mL/min assessed at recruitment
Liver function
liver failure assessed at recruitment by clinical history and examination of ALT, AST and total bilirubin, and other contraindications to metformin use
Impaired renal function with creatinine clearance < 60 mL/min assessed at recruitment, liver failure assessed at recruitment by clinical history and examination of ALT, AST and total bilirubin, and other contraindications to metformin use
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05929495 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages